tucidinostat
Showing 1 - 9 of 9
HR+/HER2- Breast Cancer Trial (Tucidinostat, nab-paclitaxel)
Not yet recruiting
- HR+/HER2- Breast Cancer
- Tucidinostat
- nab-paclitaxel
- (no location specified)
Nov 21, 2022
Triple Negative Breast Cancer Trial in Guangzhou (Capecitabine, Tucidinostat)
Recruiting
- Triple Negative Breast Cancer
- Capecitabine
- Tucidinostat
-
Guangzhou, Guangdong, ChinaSun-yat sen university cancer center
Nov 1, 2022
Breast Cancer Trial in Guangzhou (Tucidinostat, Capecitabine, Endocrine Therapy)
Recruiting
- Breast Cancer
- Tucidinostat
- +2 more
-
Guangzhou, Gangdong, ChinaShusen Wang
Nov 1, 2022
HR+ Metastatic Breast Cancer Patients Previously Treated With
Recruiting
- Breast Cancer
- Tucidinostat
-
Beijing, Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
Mar 3, 2022
Diffuse Large B-cell Lymphoma Trial in Beijing, Shanghai (R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and
Recruiting
- Diffuse Large B-cell Lymphoma
- R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)
- +2 more
-
Beijing, Beijing, China
- +1 more
Aug 8, 2021
Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)
Recruiting
- Peripheral T Cell Lymphoma
- Azacitidine Injection
- +6 more
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Nov 8, 2022
Breast Cancer Trial in Guangzhou (Tucidinostat, Exemestane, Ovarian function suppression)
Unknown status
- Breast Cancer
- Tucidinostat
- +2 more
-
Guangzhou, Guangdong, ChinaThe first affiliated hospital of Sun Yat-Sen university
Jul 22, 2020
Diffuse Large B-cell Lymphoma Trial in Changchun (Tucidinostat)
Recruiting
- Diffuse Large B-cell Lymphoma
- Tucidinostat
-
Changchun, Jilin, ChinaThe First Bethune Hospital of Jilin University
Dec 4, 2020